TransMedics Group Inc. (TMDX)
TransMedics (TMDX) Crossed Above the 50-Day Moving Average: What That Means for Investors
TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 50-day moving average, which suggests a short-term bullish trend.
TransMedics (TMDX) Just Overtook the 20-Day Moving Average
From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
TransMedics (TMDX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TransMedics: Growth Tailwinds Should Provide Upside In 2026
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the company's valuation in the long term.
TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuation attractive and expectations more reasonable. Industry data signals a strong Q4 ahead, supporting the case for near-term upside in TMDX.
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
TransMedics Group, Inc. ( TMDX ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Matthew Mardula - William Blair & Company L.L.C.
TransMedics (TMDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics: I'm More Bullish Than Ever
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion development, position TMDX for significant growth and market expansion. International markets, especially Europe, Middle East, and Australia, offer substantial growth opportunities and diversification beyond the US core business.
TransMedics: Upcoming Trials Are Critical
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. liver market. TMDX's next-gen heart and lung programs, kidney device development, and international expansion could also drive significant growth longer term.
TransMedics: Just Like The CEO, I'm Buying
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrated logistics, and service model create a strong moat, with next-gen products and international expansion as major growth catalysts. Financials are robust: Q2 2025 revenue grew 37.7% YoY, margins improved, and guidance was raised.
